Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Diabetes

Journal Scan / Research · October 08, 2024

Beta-Hydroxybutyrate Levels and the Risk of Diabetic Ketoacidosis in Adults With Type 1 Diabetes Treated With Sotagliflozin

Diabetes Technology & Therapeutics

 

Additional Info

Diabetes Technology & Therapeutics
Beta-Hydroxybutyrate Levels and Risk of Diabetic Ketoacidosis in Adults with Type 1 Diabetes Treated with Sotagliflozin
Diabetes Technol. Ther. 2024 Sep 01;26(9)618-625, S Boeder, MJ Davies, JB McGill, R Pratley, M Girard, P Banks, J Pettus, S Garg

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading